Innovation Theater 5
Supported By: Sanofi and Regeneron Pharmaceuticals, Inc.

Program Description

Please join Pulmonology expert Bartolome Celli, MD, in a review of the associations between inflammatory pathways and chronic obstructive pulmonary disease (COPD). Dr. Celli will discuss the importance of stratifying patients with COPD based on different clinical phenotypes that can impact disease severity and progression.

The objectives of this program are to:

• Discuss the current clinical burden of COPD exacerbations and progressive lung function decline
• Review the complex pathophysiology of COPD and the various inflammatory pathways which may contribute to disease progression
• Assess current challenges associated with the management of COPD as well as the importance of clearly identifying specific COPD patient types

With high worldwide morbidity and mortality as well as substantial direct and indirect healthcare costs,¹ COPD is a progressive airway disease characterized by acute exacerbations, decreased lung function, and high symptom burden.^2,3 Low FEV₁ is a risk factor for COPD exacerbations, which in turn are associated with increased rates of lung function decline—creating a downward spiral of respiratory damage, COPD exacerbations, worsening symptoms, and reduced quality of life.^4-6 Even with current standard of care treatments, many patients with COPD continue to experience frequent exacerbations.⁷

Our understanding of the pathophysiology and molecular mechanisms of COPD—including the heterogeneity of different inflammatory pathways that drive the disease—is evolving rapidly. With this knowledge, there is an ongoing opportunity to define subsets of patients based on specific endotypes (eg, type 2 inflammation) and/or phenotypes (eg, current smokers).³

Speakers

Bartolome Celli, MD
Clinical Research Foundation
Boston, MA

FEV₁, forced expiratory volume in 1 second.

References

1. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-596.
2. Celli B, Fabbri L, Criner G, et al. Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision. Am J Respir Crit Care Med. 2022;206(11):1317-1325.
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2025. Accessed March 11, 2025. https://goldcopd.org/2025-gold-report/
4. Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324-330.
5. Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653-661.
6. de la Loge C, Tugaut B, Fofana F, et al. Relationship between FEV₁ and patient-reported outcomes changes: results of a meta-analysis of randomized trials in stable COPD. Chronic Obstru Pulm Dis. 2016;3(2):519-538.
7. Halpin DMG, Dransfield MT, Han MK, et al. The effect of exacerbation history on outcomes in the IMPACT trial. Eur Respir J. 2020;55(5):1901921.

US.PUL.25.04.0011 04/2025